key: cord-0311351-p8ii4bfe
authors: Charmetant, X.; ESPI, M.; Barba, T.; Ovize, A.; Morelon, E.; Thaunat, O.
title: Predictive factors of response to 3rd dose of COVID-19 mRNA vaccine in kidney transplant recipients
date: 2021-08-30
journal: nan
DOI: 10.1101/2021.08.23.21262293
sha: 9c4cb53b2d87d2fbc8751b2ef32bfb74faa7f370
doc_id: 311351
cord_uid: p8ii4bfe

Only a minority of kidney transplant recipients (KTRs) develop protective neutralizing titers of anti-receptor binding domain of spike protein (RBD) IgG after two doses of mRNA COVID-19 vaccine. Administration of a third dose of mRNA vaccine to KTRs with sub-optimal response increase anti-RBD IgG titers but with high inter-individual variability. Patients with the higher response rate to the third dose of vaccine can be identified by the presence of low anti-RBD IgG titers and spike-specific CD4+ T cells in their circulation 14 days after the second dose.

Kidney transplant recipients (KTRs) carry a very high risk of death due to COVID-19 in case of infection by SARS-Cov-2 [1] [2] [3] [4] [5] . This vulnerable population has therefore been prioritized for vaccination. However, after the "standard" 2 doses of mRNA vaccine only few KTRs develop appropriate levels of anti-receptor binding domain of spike protein (RBD) IgG [6] [7] [8] , which are responsible for the neutralization of the virus and the protection against COVID-19 9 . Accordingly, we and others have reported cases of vaccinated KTRs with (sometime severe forms of) COVID-19 10,11 .

Preliminary reports suggest that a third dose (D3) of vaccine may improve the humoral response in some patients 12, 13 . In this prospective observational study, we aimed at describing the serological response of KTRs to D3 of mRNA vaccine and identifying the variables associated with response to D3. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 30, 2021. ; https://doi.org/10.1101/2021.08.23.21262293 doi: medRxiv preprint 5

The study protocol was approved by Institutional Review Board (approval number: 2020-A02918-31, Comité de Protection des Personnes Sud-Est I). Vaccination with 2 doses of BNT162b2 mRNA vaccine (Pfizer-BioNtech) was offered to KTRs from Lyon University Hospital. According to the French health authority, a third vaccine injection was offered to all patients whose IgG titers were below 142 BAU/mL, the threshold correlating with positivity of functional neutralizing assay 14 .

The IgG antibodies directed against the Receptor Binding Domain (RBD) of the spike glycoprotein of the SARS-Cov2 were detected by a chemiluminescence technique, using the Maglumi® SARS-CoV-2 S-RBD IgG test (Snibe Diagnostic, Shenzen, China) on a Maglumi 2000® analyser (Snibe Diagnostic), according to the manufacturer's instructions. This test displays clinical sensitivity and specificity of 100% and 99.6%, respectively. As recommended by the WHO, the obtained titer was then expressed as binding arbitrary units/mL (BAU/mL); correction factor for Maglumi®: 4.33.

Spike specific CD4+ T cells response was quantified in the circulation of the KTRs using the QuantiFERON® SARS-CoV2 test (Qiagen, Netherlands), a commercially available Interferon Gamma Releasing Assay (IGRA), according to the manufacturer's instructions.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Anti-RBD IgG and the interferon-γ secreted by circulating spike-specific CD4+ T cells were monitored 14 days after the second dose (D2) of BNT162b2 vaccine (Pfizer-BioNtech) in 93 consecutive KTRs from Lyon University Hospital, 5 of whom had previous history of COVID-19 (black diamonds; Figure 1A -C).

Following French health authorities recommendation, a third dose (D3) of vaccine was injected to 66 patients of the initial cohort, (dashed line in Figures 1B-E) . Overall, the clinical tolerance of the D3 was good. The main side-effect was pain at the site of injection, which occurred with the same incidence after each of the three doses (50% of patients). Five patients had fever <39°C for maximum two days after D3.

Forty-two percent (28/66) of KTRs that received D3 reached 142 BAU/mL of anti-RBD IgG (responders). In univariate analysis ( Table 1) , responders to D3 were younger than non-responders (43.2+/-13.1 vs 52.1+/-12.5 years; p=0.011), had lower baseline creatinine level (114+/-33 vs 143+/-50 µmol/L; p=0.015), and were less frequently exposed to mycophenolate mofetil (19/28 vs 35/38, p=0.021). In addition, presence of low titers (i.e. above threshold of positivity but below 142 BAU/mL) of anti-RBD IgG ( Figure 1D ), and circulating spike-specific CD4+ T cells (Table 1, Figure 1E ) after D2, were both associated with a better serological response to D3. In multivariate analysis, these last two biomarkers were the only remaining independent predictive variables allowing identifying KTRs responders to D3 (OR 15.9, IC95% [3.87−87.46], p<0.001, for low anti-RBD IgG titers; and 8.03, IC95% [1.62−52.59], p=0.017 for positive CD4+ T cells IGRA; Figure 1F ). Furthermore, combining these two information, we observed that the probability to respond to D3 in KTRs was the highest in patients positive for both tests (89%, Figure 1G ). The response rate decreased to 72% in KTRs with only All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 30, 2021. ; https://doi.org/10.1101/2021.08.23.21262293 doi: medRxiv preprint 8 low anti-RBD IgG after D2 and 56% in those with only a positive CD4+ T cells IGRA.

Finally, only 7% KTRs in whom both tests were negative after D2 did develop an optimal serological response after D3.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

All authors declared no conflicts of interest.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Anti-SARS-Cov2 S-RBD humoral response assessment Ten microliters of serum were incubated in the appropriate buffer with magnetic microbeads covered with S-RBD recombinant antigen, in order to form immune complexes. After precipitation in a magnetic field and washing, ABEI (N-(4-Aminobutyl)-N-ethylisoluminol)-stained anti-human IgG antibodies were added to the samples. After a second magnetic separation and washing, the appropriate reagents were added to initiate a chemiluminescence reaction. When necessary, sera were diluted sequentially up to 1:1000.

One milliliter blood was distributed in each tube of the assay: (i) uncoated tube: negative control/background noise, (ii) tube coated with mitogen: positive control, and (iii) tube coated with HLA-II restricted 13-mers peptides derived from the entire SARS-CoV2 Spike glycoprotein used to stimulate CD4+ T cells. After 20 hours of culture at 37°C, tubes were centrifugated 15 minutes at 2500g, and stored at 4°C before INFᵧ quantification in the supernatant by ELISA.

The CD4+ T cell assay value was the difference between tube (iii) and the negative control (i).

Categorical variables were expressed as percentages and compared with a two-sided chi-square test or a two-sided Fisher's exact test when the conditions for a chi-square were not fulfilled. Continuous variables were expressed as mean ± SD and compared All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 30, 2021. ; https://doi.org/10.1101/2021.08.23.21262293 doi: medRxiv preprint

IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)

Is COVID-19 infection more severe in kidney transplant recipients?

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Factors associated with COVID-19-related death using OpenSAFELY

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

(D) or circulating spike specific CD4+ T (CD4 IFN) cells (E) after D2. F. A multivariate analysis was conducted to identify the variables independently associated with a titer of anti-RBD IgG > 142 BAU/mL after D3. Forest plot shows the odd ratio and the 95% confidence interval for the variables with p<0.10 in the univariate analysis. G. The Mann-Whitney test for unpaired data and Wilcoxon test for paired data. **, p<0.01; ****, p<0.0001.All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 30, 2021. ; https://doi.org/10.1101/2021.08.23.21262293 doi: medRxiv preprint using t-tests or as median and compared using Mann Whitney test for variables with non-normal distribution. Wilcoxon test was used for paired data.Logistic regression models were used in both univariate and multivariate analyses. All the explanatory variables significantly associated with outcomes in univariate analyses (p-value < 0.10) were included in multivariate models. Stepwise regression analyses with bidirectional elimination were then performed, using Aikake Information Criterion to select the most fitting final multivariate models.All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 30, 2021. ; https://doi.org/10.1101/2021.08.23.21262293 doi: medRxiv preprint